Triple-class virologic failure in HIV-infected patients undergoing antiretroviral therapy for up to 10 years

Archives of Internal Medicine

Volumn 170, Issue 5, 2010, Pages 410-419

  Lodwick, Rebecca ^c   Costagliola, Dominique ^a   Reiss, Peter ^b   Torti, Carlo ^c   Teira, Ramón ^c   Dorrucci, Maria ^c   Ledergerber, Bruno ^c   Mocroft, Amanda ^c   Podzamczer, Daniel ^c   Cozzi Lepri, Alessandro ^c   Obel, Niels ^c   Masquelier, Bernard ^d   Staszewski, Schlomo ^c   García, Federico ^e   De Wit, Stephane ^c   Castagna, Antonella ^c   Antinori, Andrea ^c   Judd, Ali ^c   Ghosn, Jade ^f   Touloumi, Giota ^c   Mussini, Cristina ^c   Duval, Xavier ^g   Ramos, José ^c   Meyer, Laurence ^h   Warsawski, Josiane ⁱ   Thorne, Claire ^c   Masip, Joan ^c   Pérez Hoyos, Santiago ^c   Pillay, Deenan ^c   Van Sighem, Ard ^b   Caputo, Sergio Lo ^c   Günthard, Huldrych ^c   Paredes, Roger ^c   De Luca, Andrea ^c   Paraskevis, Dimitrios ^c   Fabre Colin, Céline ^c   Kjaer, Jesper ^c   Chêne, Geǹvieve ^c   Lundgren, Jens D ^c   Phillips, Andrew N ^j   more..

^a ANRS CO4 FHDH   (France)

^b ATHENA   (Netherlands)

^c Italian Master Cohort ^*

^d ANRS CO3 AQUITAINE   (France)

^e CASCADE ^*

^f ANRS CO6 PRIMO   (France)

^g ANRS CO8 COPILOTE   (France)

^h ANRS CO2 SEROCO   (France)

ⁱ ANRS CO1 EPF   (France)

^j UK CHIC   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR PLUS RITONAVIR; ATAZANAVIR PLUS RITONAVIR; DARUNAVIR PLUS RITONAVIR; EFAVIRENZ; FOSAMPRENAVIR PLUS RITONAVIR; INDINAVIR PLUS RITONAVIR; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RITONAVIR PLUS SAQUINAVIR; RITONAVIR PLUS TIPRANAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR;

ADOLESCENT; ADULT; ARTICLE; DRUG WITHDRAWAL; EUROPE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; THERAPY EFFECT; TREATMENT DURATION; TREATMENT FAILURE; CLINICAL TRIAL; DRUG EFFECT; KAPLAN MEIER METHOD; MIDDLE AGED; MULTICENTER STUDY; PROPORTIONAL HAZARDS MODEL; VIRUS LOAD;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; EUROPE; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; KAPLAN-MEIERS ESTIMATE; LIFE EXPECTANCY; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; REVERSE TRANSCRIPTASE INHIBITORS; RITONAVIR; TREATMENT FAILURE; VIRAL LOAD; YOUNG ADULT;

EID: 77950356923     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinternmed.2009.472     Document Type: Article

References (31)

1. Bhaskaran K, Hamouda O, Sannes M, et al; CASCADE Collaboration. Changes in the risk of death after HIV seroconversion compared with mortality in the general population. JAMA. 2008;300(1):51-59. (Pubitemid 351920404)
2. Lewden C, Chene G, Morlat P, et al; Agence Nationale de Recherches sur le Sida et les Hepatites Virales (ANRS) CO8 APROCO-COPILOTE Study Group; Agence Nationale de Recherches sur le Sida et les Hepatites Virales (ANRS) CO3 AQUITAINE Study Group. HIV-infected adults with a CD4 cell count greater than 500 cells/mm(3) on long-term combination antiretroviral therapy reach same mortality rates as the general population. J Acquir Immune Defic Syndr. 2007;46(1):72-77.
3. Lohse N, Obel N, Kronborg G, et al. Declining risk of triple-class antiretroviral drug failure in Danish HIV-infected individuals. AIDS. 2005;19(8):815-822. (Pubitemid 40834752)
4. Phillips AN, Leen C, Wilson A, et al; UK Collaborative HIV Cohort (CHIC) Study. Risk of extensive virological failure to the three original antiretroviral drug classes over long-term follow-up from the start of therapy in patients with HIV infection: an observational cohort study. Lancet. 2007;370(9603):1923-1928. (Pubitemid 350193334)
5. Mocroft A, Ledergerber B, Viard JP, et al; EuroSIDA Study Group. Time to virological failure of 3 classes of antiretrovirals after initiation of highly active antiretroviral therapy: results from the EuroSIDA Study Group. J Infect Dis. 2004;190(11):1947-1956. (Pubitemid 39564700)
6. Sabin CA, Hill T, Lampe F, et al; UK Collaborative HIV Cohort (UK CHIC) Study Group. Treatment exhaustion of highly active antiretroviral therapy (HAART) among individuals infected with HIV in the United Kingdom: multicentre cohort study. BMJ. 2005;330(7493):695-698.
7. Zaccarelli M, Tozzi V, Lorenzini P, et al; Collaborative Group for Clinical Use of HIV Genotype Resistance Test (GRT) at National Institute for Infectious Diseases Lazzaro Spallanzani. Multiple drug class-wide resistance associated with poorer survival after treatment failure in a cohort of HIV-infected patients. AIDS. 2005;19(10):1081-1089.
8. Tozzi V, Zaccarelli M, Bonfigli S, et al; Collaborative Group for Clinical Use of HIV Genotype Resistance Test. Drug-class-wide resistance to antiretrovirals in HIV-infected patients failing therapy: prevalence, risk factors and virological outcome. Antivir Ther. 2006;11(5):553-560.
9. Napravnik S, Keys JR, Quinlivan EB, Wohl DA, Mikeal OV, Eron JJ Jr. Triple-class antiretroviral drug resistance: risk and predictors among HIV-1-infected patients. AIDS. 2007;21(7):825-834. (Pubitemid 46573154)
10. Mocroft A, Horban A, Clotet B, et al; EuroSIDA Study Group. Regional differences in the risk of triple class failure in European patients starting combination antiretroviral therapy after 1 January 1999. HIV Med. 2008;9(1):41-46.
11. Ledergerber B, Lundgren JD, Walker AS, et al; PLATO Collaboration. Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes. Lancet. 2004;364(9428):51-62.
12. Costagliola D, Potard V, Duvivier C, et al; French Hospital Database on HIV. Impact of newly available drugs on clinical progression in patients with virological failure after exposure to three classes of antiretrovirals. Antivir Ther. 2005;10(4):563-573. (Pubitemid 41059204)
13. Hammer SM, Eron JJ Jr, Reiss P, et al; International AIDS Society-USA. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society USA panel. JAMA. 2008;300(5):555-570.
14. DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents - A Working Group of the Office of AIDS Research Advisory Council (OARAC). Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed December 15, 2008.
15. Gazzard BG; BHIVA Treatment Guidelines Writing Group. British HIV Association guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Med. 2008;9(8):563-608.
16. Clumeck N, Pozniak A, Raffi F; EACS Executive Committee. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of HIV-infected adults. HIV Med. 2008;9(2):65-71. (Pubitemid 351228129)
17. Riddler SA, Haubrich R, DiRienzo AG, et al; AIDS Clinical Trials Group Study A5142 Team. Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med. 2008;358(20):2095-2106.
18. World Health Organization, HIV/AIDS Department. Priority interventions: HIV/AIDS prevention, treatment and care in the health sector: Version 1.2: April 2009. http://www.who.int/hiv/pub/priority-interventions-web.pdf. Accessed August 31, 2009.
19. Collaboration of Observational HIV Epidemiological Research Europe (COHERE) Study Group. Response to combination antiretroviral therapy: variation by age. AIDS. 2008;22(12):1463-1473.
20. Kjaer J, Ledergerber B. HIV cohort collaborations: proposal for harmonization of data exchange. Antivir Ther. 2004;9(4):631-633. (Pubitemid 39150221)
21. Fagard C, Descamps D, Dubar V, et al. Efficacy and safety of raltegravir plus etravirine and darunavir/ritonavir in treatment-experienced patients with multidrug-resistant virus: 48-week results from the ANRS 139 TRIO trial. Presented at: the 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention; July 19-22, 2009; Cape Town, South Africa.
22. Lazzarin A, Clotet B, Cooper D, et al; TORO 2 Study Group. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med. 2003;348(22):2186-2195. (Pubitemid 36618129)
23. Steigbigel RT, Cooper DA, Kumar PN, et al; BENCHMRK Study Teams. Raltegravir with optimized background therapy for resistant HIV-1 infection.NEngl J Med. 2008;359(4):339-354.
24. Gulick RM, Lalezari J, Goodrich J, et al; MOTIVATE Study Teams. Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med. 2008;359 (14):1429-1441.
25. Cooper DA, Steigbigel RT, Gatell JM, et al; BENCHMRK Study Teams. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med. 2008;359(4):355-365.
26. Branãs F, Berenguer J, Sanchez-Conde M, et al. The eldest of older adults living with HIV: response and adherence to highly active antiretroviral therapy. Am J Med. 2008;121(9):820-824.
27. Barclay TR, Hinkin CH, Castellon SA, et al. Age-associated predictors of medication adherence in HIV-positive adults: Health beliefs, self-efficacy, and neurocognitive status. Health Psychol. 2007;26(1):40-49.
28. Sabin CA, Lee KJ, Dunn D, et al. Treatment switches after viral rebound in HIV-infected adults starting antiretroviral therapy: multicentre cohort study. AIDS. 2008;22(15):1943-1950.
29. Benzie AA, Bansi LK, Sabin CA, et al; United Kingdom Collaborative HIV Cohort (CHIC) Study Group. Increased duration of viral suppression is associated with lower viral rebound rates in patients with previous treatment failures. AIDS. 2007;21(11):1423-1430.
30. Smith CJ, Phillips AN, Dauer B, et al. Factors associated with viral rebound among highly treatment-experienced HIV-positive patients who have achieved viral suppression. HIV Med. 2009;10(1):19-27.
31. Phillips AN, Walker AS. Drug switching and virologic-based endpoints in trials of antiretroviral drugs for HIV infection. AIDS. 2004;18(3):365-370.